European Heart Journal Advance Access published March 16, 2016
CLINICAL RESEARCH
EuropeanHeartJournal
doi:10.1093/eurheartj/ehw099 Heart failure/cardiomyopathy
Fluid status telemedicine alerts for heart failure:
a randomized controlled trial
Michael Bo¨hm1*, Helmut Drexler2†, Hanno Oswald2, Karin Rybak3, Ralph Bosch4,
Christian Butter5, Gunnar Klein6, Bart Gerritse7, Joao Monteiro8, Carsten Israel9,
Dieter Bimmel10, Stefan Ka¨ab11, Burkhard Huegl12, and Johannes Brachmann13,
on Behalf of the OptiLink HF Study Investigators
1DepartmentofInternalMedicineIII,Cardiology,AngiologyandIntensiveCareMedicine,SaarlandUniversityHospital,KirrbergerStrasse1,Homburg/Saar66424,Germany;
2DepartmentofCardiologyandAngiology,HannoverMedicalSchool,Hannover,Germany;3KardiologischePraxis,Dessau,Germany;4CardioCentrumLudwigsburg-Bietigheim,
Ludwigsburg,Germany;5HerzzentrumBrandenburg,Bernau,Germany;6HerzimZentrum,KardiologischePraxis,Hannover,Germany;7MedtronicBakkenResearchCenter,
Maastricht,TheNetherlands;8MedtronicPLC,Minneapolis,USA;9DepartmentofInternalMedicine–Cardiology,EvangelischesKrankenhausBielefeld,Bielefeld,Germany;
10DepartmentofInternalMedicine–Cardiology,SanktMarienHospital,Bonn,Germany;11DepartmentofMedicine1,Ludwig-MaximiliansUniversityHospital,Munich,Germany;
12DepartmentofInternalMedicine–Cardiology,MarienhausKlinikum,Neuwied,Germany;and13DepartmentofInternalMedicineII,Cardiology,AngiologyandPneumology,
KlinikumCoburgGmbH,Coburg,Germany
Received19August2015;revised21December2015;accepted22February2016
Aims Hospitaladmissionsarefrequentlyprecededbyincreasedpulmonarycongestioninheartfailure(HF)patients.This
studyevaluatedwhetherearlyautomatedfluidstatusalertnotificationviatelemedicineimprovesoutcomeinHF
patients.
.....................................................................................................................................................................................
Methods Patientsrecentlyimplantedwithanimplantablecardioverterdefibrillator(ICD)withorwithoutcardiacresynchroniza-
andresults tiontherapywereeligibleifoneofthreeconditionswasmet:priorHFhospitalization,recentdiuretictreatment,or
recentbrainnatriureticpeptideincrease.Eligiblepatientswererandomized(1:1)tohavefluidstatusalertsautomatically
transmittedasinaudibletextmessagealertstotheresponsiblephysicianortoreceivestandardcare(noalerts).Inthe
interventionarm,followingatelemedicinealert,aprotocol-specifiedalgorithmwithremotereviewofdevicedataand
telephonecontactwasprescribedtoassesssymptomsandinitiatetreatment.Theprimaryendpointwasacompositeof
all-causedeathandcardiovascularhospitalization.Wefollowed1002patientsforanaverageof1.9years.Theprimary
endpointoccurredin227patients(45.0%)intheinterventionarmand239patients(48.1%)inthecontrolarm[hazard
ratio,HR,0.87;95%confidenceinterval(CI),0.72–1.04;P¼0.13].Therewere59(11.7%)deathsintheintervention
armand63(12.7%)inthecontrolarm(HR,0.89;95%CI,0.62–1.28;P¼0.52).Twenty-fourpercentofalertswerenot
transmittedand30%werefollowedbyamedicalintervention.
.....................................................................................................................................................................................
Conclusion AmongICD patientswithadvancedHF,fluidstatustelemedicinealertsdidnotsignificantlyimprove outcomes.
Adherencetotreatmentprotocolsbyphysiciansandpatientsmightbechallengeforfurtherdevelopmentsinthe
telemedicinefield.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Heartfailure † Diseasemanagement † Telemedicine † Cardiacresynchronizationtherapy † Implantable
defibrillator
*Correspondingauthor.Tel:+4968411623372,Fax:+496841162336,Email:michael.boehm@uniklinikum-saarland.de
†Deceased.
PublishedonbehalfoftheEuropeanSocietyofCardiology.Allrightsreserved.&TheAuthor2016.Forpermissionspleaseemail:journals.permissions@oup.com.
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Page2of10 M.Bo¨hmetal.
Translational perspective
Ourstudyisarandomizedcontrolledtrialshowingnosignificantbenefitofaspecifictelemonitoringapproachusingimplant-based
intrathoracicimpedancemeasurementsinpatientswithheartfailure(HF).Thealerttechnology,inaudibletopatients,didnotdecrease
hospitalizations.Theobservedrateoftelemonitor-guidedmedicalinterventionwaslowdespiteintensiveinstructionofpatientsand
physicians.Thisimportantfindingmaydemonstratethesituationmoreclosetoreallifeandclinicalpractice,highlightingthechallenges
associatedwithsuchadiseasemanagementapproach.Giventheconsiderable,andlargelyunmitigatedburdenofHF,thepotentialfor
telemonitoringtoimprovethemanagementofpatientswithHFissubstantial,providedovercomingtheobstaclesidentifiedinOptimization
ofHeartFailureManagementusingOptiVolTM FluidStatusMonitoringandCareLinkTM,whichmaybeanevengreaterbarrierinclinical
practicethanintheclinicaltrialconditionsreportedherein.
Introduction (CRT-D)withinthepreceding3–21daysaccordingtoguidelinerecom-
mendedindications.12Ofnote,CRT-DpatientsneededQRS≥120ms
Heartfailureisahighlyprevalentsyndrome,affectingover23million andleftventricularenddiastolicdiameter ≥55mm.Allpatientsre-
peopleworldwide.1,2Althoughimprovementshavebeenmadein ceivedaMedtronicICDorCRT-Dwiththecapabilityofintrathoracic
fluidstatusmonitoringandtelemedicinefunctionality.Inaddition,one
the treatment of chronic HF, morbidity, and mortality remain
high.3In (cid:2)90%ofcases,patientshospitalizedforHFpresentwith ofthreeconditionshadtobemet:eitherHFhospitalizationwithin
the last 12 months, intravenous/oral diuretic treatment within 30
pulmonarycongestionwithincreasedfillingpressuresandvolume
days,orincreasedbrainnatriureticpeptide(BNP)/N-terminal-pro-BNP
overload4 often preceding the development of symptoms and
within30days.Cut-offswere.400pg/mLforBNPand.450pg/mLin
hospitalization.5,6Avarietyofstrategieshasbeentestedleveraging
patients,50years,.900pg/mLinpatients50–75years,.1800pg/mL
implantabletechnologiesfortheearlydetectionofcongestion,thus inpatients .75yearsforN-terminal-pro-BNP.Patientswithchronic
enablinginterventioninanefforttoavoidhospitalization.5–9How-
renalfailurerequiringdialysis,severechronicobstructivepulmonary
ever,theseattemptshavehadmixedresults.Inapreviousstudy, disease,orwithplannedhearttransplantationwereineligible.
intrathoracicimpedancemonitoringwithaudiblepatientalertdid Thestudydesignrequiredfollow-upvisitsevery6monthsafterran-
notreduceall-causemortalityorHFhospitalizationsinthemanage- domizationupto18months.Inthefirstquarterof2011,duringthe
mentofpatientswithHF.7Infact,usingthisdiagnosticinformation courseofthetrial,theprotocolwasrevisedtoextendfollow-upuntil
allparticipantshadreachedthe18-monthvisit.Therevisionwasat
togetherwithanalertaudibleforpatientsresultedinmorehospita-
therequestofthedatasafetymonitoringboard(DSMB)duetoslower
lizationsandoutpatientvisits.Aproportionofhospitalizationsmay
thananticipatedenrolment.
wellhavebeendrivenmainlybytheaudiblealertitselfandtheneed
The executive committee designedandoversawthe conductof
ofpatients(andalsophysicians)toresolvethesituationeveninthe
thetrialanddataanalysisincollaborationwiththesponsor,Medtronic.
absenceofsignsandsymptomsforHFdeterioration.Recently,find-
ThetrialwasmonitoredbyanindependentDSMB.Datawerecollected
ingsfromtheIN-TIMEstudy10showedamodestbenefitinaclinical
andmanagedbythesponsorandanalysedaccordingtoapre-specified
scoreconsistingofall-causedeath,overnighthospitalizationforHF, statisticalanalysisplan.Thetrialprotocolwasapprovedbytheethical
changeinNewYorkHeartAssociation(NYHA)classification,and committeesoftheindividualcentresandisavailablealongwiththestat-
changeinpatientglobalself-assessment.However,arecentsystem- isticalanalysisplanateurheartj.oxfordjournals.org.Allpatientsprovided
aticmeta-analysisofninerandomizedcontrolledtrialsonremote writteninformedconsentpriortoenrolmentintothetrial.
monitoringofimplantablecardioverterdefibrillator(ICD)patients
Randomization
involving6469patientsfailedtoshoweffectsonall-causemortality,
cardiovascularmortality,andhospitalization.11 Patientswererandomlyassigned1:1tohavetheirdevicessettoauto-
maticallytransmitfluidindextelemedicinealertsortonottransmit
TheOptiLinkHF(OptimizationofHeartFailureManagement
usingOptiVolTM FluidStatusMonitoringandCareLinkTM)study alerts.Therandomizationwasdoneusingacentralized,concealedpro-
cessimplementedbythesponsor,andstratifiedbyNYHAclass,history
wasdesignedtoinvestigatewhetherearlydetectionofpulmonary
ofatrialfibrillation(AF),historyofventriculararrhythmia(VT/VF),and
congestionviatelemedicinewithadefinedinterventionalgorithm
ischaemicstatus.Therandomallocationsequencewithrandomblocks
reducesall-causedeathandcardiovascular(CV)hospitalizationsin
offourwascomputergenerated.Controlpatientswerenotsetupinthe
chronicHFpatientswithanICDcomparedwithpatientswithout telemonitoringsystemsothatnoaccidentalcrossovercouldoccur.
telemedicineaccess.
Intervention algorithm
Asdescribedpreviously,13patientsrandomizedtotheinterventionarm
Methods
hadtelemedicinealertsenabled,triggeredbyintrathoracicfluidindex
thresholdcrossing(FTC),whichwasprogrammedattheinvestigator’s
Study design and participants
discretion.Thefluidstatusmonitoringalgorithmdetectschangesin
OptimizationofHeartFailureManagementusingOptiVolTMFluidStatus thoracicimpedanceresultingfromaccumulationofintrathoracicfluid
MonitoringandCareLinkTM wasaprospective,multi-centre,rando- asanearlysignofdevelopingcardiacdecompensation.
mized,andunblindedstudyconductedinGermany.Eligiblepatients Alertswereautomaticallytransmittedviatextmessagetothere-
wereinstableNYHAclassIIorIIIHF,leftventricularejectionfraction sponsiblephysicianbutwere‘silent’(inaudible)tothepatient.Following
(LVEF)≤35%,andreceivedamarket-releasedICD(newlyimplantedor atelemedicinealert,aprotocol-specifiedinterventionalgorithm,aspre-
replacement) with or without cardiac resynchronization therapy viouslyshowninFigure2intheOptiLinkHFdesignpaper13wasfollowed
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Fluidstatustelemedicinealertsforheartfailure Page3of10
withfollow-upactionsbeingdocumentedonTelemedicineAlertEvalu- implantedwithasingle-chamberICD(23.3%),dual-chamberICD
ationForms(TAEFs).Briefly,theHF-specificdevicedatawerereviewed (14.2%), or CRT-D (62.6%) prior to enrolment. Mean age was
remotely,andthepatientwascontactedwithin2workingdaysbyphone 66.3+10.4years,79.7%weremale.Patients’demographicsand
toevaluateconditionandHFstatusandtotakeappropriatemeasures. clinicalcharacteristicsareshowninTable1.Baseduponobserved
Upto3furthertelemedicine-guidedremotecontactswithreviewofde-
imbalancesingenderandhistoryofHFhospitalization,formalstat-
vicedataandHFstatuswerescheduledinthe2weeksfollowingthe
isticaltestingwasdone,whichconfirmedtheimbalances.I.V.diure-
alert.Whencontactingpatientsonthebasisoftelemonitoreddata,
ticspriortorandomizationwasslightlyimbalanced.
theinvestigatorsusedastandardizedtelephoneinterviewtoestablish
Patientswerefollowedfor22.9+18.2months.Figure1shows
whetherthepatient’soverallconditionhadworsenedandwhether
thestudyflowinCONSORTformat.Allpatientsreceivedtreatment
thepatientwasregularlytakingprescribeddrugs.Patientsrandomized
tothecontrolgroupdidnothaveaccesstotelemonitoring,although pertheirrandomizedallocation,with505receivinganalertenabled
devicedatacouldbeaccessedintheclinic. system(intervention)and497receivinganalertdisabledsystem(con-
trol).Thenumberofpatientswithsignedre-consentandlong-term
Study outcomes
datafollow-upavailablewas175(34.6%)intheinterventionarmand
Theprimaryoutcomewasacompositeofall-causedeathandCVhos-
167(33.6%)inthecontrolarm.Theproportionofpatientswith
pitalization.Secondaryoutcomeswereall-causemortality,cardiovascu-
extended follow-up was similar between groups. Nonetheless,
lar mortality, composite of all-cause death and HF hospitalization,
someselectionbiascannotberuledout,andcautionmustbeused
CVhospitalizations,HFhospitalizations,andall-causehospitalizations
upon interpretationof data beyond 18 months of follow-up. All
duringfollow-up.
AnEventAdjudicationCommittee,blindedtothetreatmentarms,ad- 1002patientswereincludedintheanalysisperintention-to-treat.
judicatedallreportedeventsanddeaths.Foralleventsanddeaths,afinal
Endpoints
consensusclassificationwasreached.Analysesusedadjudicationresults.
Intheinterventionarm,227patientsreachedtheprimaryendpoint,
Statistical analysis comparedwith239inthecontrolarm(Table2).Event-freesurvival
Statisticalanalysiswaspre-specifiedinthestudyprotocolandastatistic- at(18,24)monthswas(59.0%,52.7%)fortheinterventiongroup
alanalysisplan.FreedomfromeventisillustratedwithKaplan–Meier and(56.1%,47.8%)forthecontrolgroup,respectively(HR,0.87;
curvesandcomparedbetweenrandomizedarmswithastratifiedlog- 95%CI,0.72–1.04;P¼0.13).Figure2Adisplaysthesurvivalcurves
ranktest.Thestratifyingvariablesaredevicetype(ICDvs.CRT-D) by treatment arm for the primaryendpoint, which were drawn
andthevariablesusedintherandomizationprocess,i.e.NYHAclass, whenthenumberofpatientsatriskwasatleast50toavoidmisin-
ischaemic,ornon-ischaemicHFaetiology,historyofVT/VF,andhistory
terpretationofestimatedsurvivalprobabilitiesthatarebasedonfew
ofAF.Hazardratios(HRs)andassociated 95%confidenceintervals
patientsatrisk.Twointerimanalyseswereperformedasplanned.
(CIs)arereportedfromstratifiedCoxproportional-hazardsregression
ThestoppingboundarieswerenotcrossedandtheDSMBrecom-
models.AllHRestimatesarefortheinterventionarmrelativetothe
mendedcontinuationofthestudy.
controlarm.Subgroupanalyseswereperformedwithuseofstratified
Therewere59deathsintheinterventionarmand63inthecon-
coxproportional-hazardsregressionmodels,havingtreatmentgroup
andabaselinefactorascovariatesalongwiththeirinteractionterm. trolarm.All-causedeathincidencesat(18,24)monthswere(6.3%,
TherateofHFhospitalizationperpatientperyearwasanalysedthrough 11.0%)and(8.5%,15.7%)respectively(HR,0.89;95%CI,0.62–1.28;
anegativebinomialregressionwithonlytreatmentarmascovariateand P¼0.52).Figure2Bdisplaysthesurvivalcurvesbytreatmentarmfor
log(follow-uptime)asanoffsetvariabletoaccountfordifferentfollow- all-causedeath.
uptimeamongthesubjects. Therewere435patientswhoexperiencedatotalof928CVhos-
Asre-consentwasoptional,long-termfollow-updatawereincluded pitalizationspost-randomization;495eventsin214patientsinthe
inanalysisonlyafterpoolabilityassessment.Patientsintheprimaryob-
intervention arm and 433 events in 221 patients in the control
jectiveanalysiscohortwhore-consentedandwerefollowedbeyond18
arm.TimetofirstCVhospitalizationwasnotdifferentbetween
monthsarecomparedagainstthosewhosurvivedto18monthsbutdid
thetreatmentandcontrolgroups(HR,0.89;95%CI,0.73–1.08;
notre-consentandexitedatthe18-monthvisitwithrespecttogender
P¼0.22).Figure2Cdisplaysthesurvivalcurvesbytreatmentarm
andtheabovementionedstratifyingvariables.Fisher’sexacttestwas
fortheCVhospitalizationendpoint.
performedforeachofthesecharacteristics.
Thestudywasdesignedtoinclude1000patientstoensure80% Post-randomizationHFhospitalizations were also similar be-
powerwhentheevent-freerateat18monthswouldbe72%inthecon- tweenthetreatmentarms.Morespecifically,thesurvivalprobabil-
trolarmand80.4%intheinterventionarm.Twointerimanalyseswere itiesfromHFhospitalizationat(18,24)monthswere(79.2%,75.4%)
scheduledwhen33and67%ofthe238expectedprimaryendpointsoc- intheinterventionarm,and(76.2%,71.8%)inthecontrolarm(HR,
curred,witha-levelsof0.0001and0.001,respectively.Thefinalanalysis 0.87;95%CI,0.67–1.12;P¼0.28).Interventionvs.ControlHRes-
wasdonewitha¼0.0495tocompensatefortheinterimanalyses,
timatesforprimaryandsecondaryobjectivesareshowninTable2.
maintainingtotaltypeIerrorat0.05.
ThenumberofHFhospitalizationsperpatientperyearasestimated
fromanegativebinomialregressionmodelwas0.24fortheInter-
Results
ventionarmand0.30fortheControlarm(P¼0.20).
Study patients Subgroup analysis
From28October2008through29April2013,atotalof1002sub- Figure3presentstheinterventionvs.controlHRsand95%CIsfor
jects were recruited from 65 centres in Germany. Patients had selectedbaselinefactors.Inaddition,thisfiguredisplaystheP-value
NYHA class II (19.4%) or III (80.6%) HF symptoms and were fortheinteractiontermbetweenthebaselinefactorandtreatment
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Page4of10 M.Bo¨hmetal.
Table1 Characteristicsofthepatientsatbaselinea
Characteristic Intervention(n5505) Control(n5497)
...............................................................................................................................................................................
Age(years) 66.1+10.1 66.4+10.7
Malesex,n(%) 390(77.2)a 409(82.3)
Body-massindex(kg/m2) 28+5 28+5
Ischaemiccardiomyopathy,n(%) 274(54.3) 271(54.5)
LVEF(%) 26.7+6.1 26.7+6.1
Ventriculartachyarrhythmia 76(15.0) 71(14.3)
HFhistory
HFhospitalizationlast12months,n(%) 344(68.1)a 297(59.8)
Intravenousdiureticslast30days,n(%) 130(25.7) 102(20.5)
IncreasedBNPlast30days,n(%) 90(17.8) 68(13.7)
IncreasedNT-pro-BNPlast30days,n(%) 274(54.3) 289(58.1)
...............................................................................................................................................................................
NYHAfunctionalclass,n(%)b
II 99(19.6) 95(19.1)
III 406(80.4) 402(80.9)
...............................................................................................................................................................................
ICDtype,n(%)
Single-chamber 111(22.0) 122(24.5)
Dual-chamber 71(14.1) 71(14.3)
Cardiacresynchronizationtherapy 323(64.0) 304(61.2)
...............................................................................................................................................................................
Comorbidities,n(%)
Hypertension 363(71.9) 355(71.4)
Diabetes 176(34.9) 173(34.8)
Kidneyfailure 171(33.9) 155(31.2)
AF 156(30.9) 148(29.8)
...............................................................................................................................................................................
Drugs,n(%)
b-Blocker 477(94.5) 459(92.4)
ACEinhibitororARB 461(91.3) 467(94.0)
Diuretic 480(95.0) 472(95.0)
Nitrateorvasodilator 41(8.1) 38(7.6)
Aldosteroneantagonist 348(68.9) 346(69.6)
aPlus–minusvaluesaremeans+standarddeviation.TherewerenosignificantdifferencesbetweenthetwogroupsexceptforHFhospitalizationwithinthelast12months
(P¼0.0069)andgender(P¼0.0495).
bNewYorkHeartAssociationclassreflectsthestatusofpatientspriortodeviceimplant.
group.Therewerenostatisticallysignificantdifferencesintheeffect wirelesslytransmittedtothetreatingphysicianthroughtelemedi-
ofinterventionon event-free survival for the primaryendpoint cine.Follow-upactionsareillustratedinFigure4.Theyweredocu-
accordingtothebaselinefactorsevaluated. mented on TAEFs in 1128 cases (64.5% of FTCs). The
protocol-requiredtelephonecontacttookplacefor1074TAEFs
Post hoc analyses
(95.2%).For983cases(87.1%)atleastoneremotecheckofdevice
Astherewasanimbalancebetweenthetwoarmswithrespecttoa datawasdone,with1,2,and3interrogationsin226(20.0%),264
historyofHFhospitalizationinthe12monthspriortorandomiza- (23.4%),and493(43.7%)cases,respectively.Atleastonesubse-
tion,theanalysiswasrepeatedadjustingforHFhospitalizationand quent telephone call with the patient took place in 995 cases
i.v.-diureticspriortorandomization(addedascovariatestothe (88.2%), with 1, 2, and 3 subsequent telephone calls in 220
stratifiedCoxregressionmodels).Noneoftheendpointshada (19.5%),272(24.1%),and503(44.6%)cases,respectively.
significantHR,exceptforthecompositeofHFhospitalizationand PatientsreportedworseningHFsymptomsatanyofthetele-
all-causedeath(HR,0.77;95%CI,0.61–0.98;P¼0.03). phone contacts for 425(37.7%) of the TAEFs. For 529 (46.9%)
TAEFs,medicalactionsweretaken,includingmedicationchanges
Alerts and compliance
for455(40.3%).Therefore,ofthe1748FTCs,30.3%ledtoamed-
Intheinvestigationalarm,therewere1748FTCsin406patients icalactionand26.0%alteredmedication.TakingintoaccountHF
(80.4%). Of these, 1324 (75.7%) generated an alert that was medicationchangeswhichoccurredwithin30daysafteraTAEF,
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Fluidstatustelemedicinealertsforheartfailure Page5of10
Figure1 Atotalof1002patientswereenrolledandrandomized[505patientstointervention(automatedintrathoracicfluidindexalerttrans-
mission)and497tocontrol(standardcareonly)].Follow-upoccurredevery6monthsuntiltheoriginalstudyendat18monthsoruntilstudy
completionforpatientsthatre-consented.Longertermfollow-upwasnotrequiredsonoattritioniscountedpost18months.
Table2 Primaryandsecondaryoutcomes
Intervention Control Hazardratio P-value Adjustedhazard Adjusted
(n5505) (n5497) (95%CI) ratioa(95%CI) P-valuea
...............................................................................................................................................................................
Primarycompositeendpoint,n(%)
DeathfromanycauseorfirstCVhospitalization 227(45.0) 239(48.1) 0.87(0.72–1.04) 0.13 0.84(0.70–1.02) 0.07
Deathfromanycause 59(6.2) 63(8.5) 0.89(0.62–1.28) 0.52 0.86(0.59–1.24) 0.41
FirstCVhospitalization 214(42.4) 221(44.5) 0.89(0.73–1.08) 0.22 0.86(0.71–1.05) 0.14
...............................................................................................................................................................................
Secondaryendpoints
DeathfromanycauseorfirstHFhospitalization,n(%) 139(27.5) 155(31.2) 0.81(0.64–1.03) 0.09 0.77(0.61–0.98) 0.03
FirstHFhospitalization,n(%) 119(23.6) 128(25.8) 0.87(0.67–1.12) 0.28 0.82(0.63–1.06) 0.13
HospitalizationsforHF,n(eventsperpatientperyear) 220(0.24) 218(0.30) – 0.20b – –
Deathfromcardiovascularcauses,n(%) 46(9.1) 48(9.7) 0.90(0.59–1.35) 0.60 0.89(0.58–1.34) 0.57
Aliveandoutofthehospital,daysperpatientperyear 337.0 330.7 – 0.34b – –
Firstanycausehospitalization,n(%) 286(56.6) 292(58.8) 0.94(0.79–1.11) 0.46 0.91(0.77–1.07) 0.26
aResultsfromaCoxproportional-hazardsregressionmodelwithhistoryofHFhospitalization(12months),IV-Diuretics(30dayspriorenrolment),andtreatmentarmas
covariates.Thismodelisstratifiedbydevicetype,NYHA,historyofAF,ischaemicstatus,andhistoryofVT/VF.
bP-valuebasedonanegativebinomialmodelwithtreatmentascovariateandlog(follow-uptime)asanoffsetvariable.
excludingchangesonorafteraCVhospitalization,equatedto0.37 Devicedatafromin-officevisitswerecollectedinbotharms.In
HFmedicationchangesperpatientper6monthsasaresultofTAEF theinterventionarm,datafromremotetelemedicineinterrogations
algorithms. werealsocollected,whichledtohighcompletenessofdevicedata
TAEFs were followed by hospitalizations adjudicated as intheinterventionarmcomparedwithmoderatecompletenessin
CV-related within30daysof anFTC in72cases(6.4% of1128 thecontrolarm.Outof554CVhospitalizationsordeathsinthe
TAEFs). In total, there were 110 CV hospitalizations within 30 interventionarm,118(21.3%)wereprecededbyadocumented
daysofanFTCfortheinterventionarm.Thus38CVhospitaliza- FTC in the preceding 30 days. In the control arm, this was the
tionswithin30daysofanFTCoccurredwhichwerenotfollowed casefor56of496events(11.3%).Restrictingtoeventswithcom-
withaTAEF. pletedevicedatainthe30precedingdays,104of374endpointsin
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Page6of10 M.Bo¨hmetal.
Figure2 Kaplan–Meiercurvesareshownforthecompositeprimaryendpointofall-causedeathandcardiovascularhospitalization(A)andits
componentsall-causedeath(B)andcardiovascularhospitalization(C).
theinterventionarm(27.8%)hadanFTCinthe30precedingdays;in Furtherposthocanalysesweredonetoevaluatetheprognostic
thecontrolarm,thisoccurredfor50of228events(21.9%).These importanceofearlyfluidthresholdcrossings(FTC),similartothe
percentageswerenotstatisticallydifferent(P¼0.12). analysis reported by Tang et al.14 Results are presented in
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Fluidstatustelemedicinealertsforheartfailure Page7of10
Figure3 Hazardratiosand95%confidenceintervalsareshownfortheprimaryoutcomeineachpre-specifiedsubgroup.Withexceptionto
cardiovasculardiseaseanddevicetype,thehazardratiosofthesubgroupsweresimilar.Allbaselinefactorsdidnotpresentstatisticallysignificant
interactions.Thedottedverticallinerepresentsthehazardratiousingallpatients(HR¼0.87).Thehorizontallinesindicatenominal95%con-
fidenceintervalsforthehazardratio.
Supplementarymaterialonline.Inbrief,earlyFTCsareassociated highcorrelationtopulmonarycapillarywedgepressureandnet
withanincreasedincidenceofprimaryendpoints.6monthsafter fluidlossduringhospitalization15butwithwiderangingsensitivity
enrolment (P¼0.0019).The studyinterventionwas associated (20.7–76.9%)andpositiveprediction(4.7–60%)toHFhospitaliza-
withalowerlateeventincidenceinthosepatientsthatremained tion.15,16Tangetal.14reportedanassociationofFTCwitha2-fold
freefromendpointsandFTCsinthefirst6months(P¼0.035). increaseriskinmortality.Thestrategytouseimplantabletechnol-
Thus,theinterventiondoesnotappeartopreventrepeatevents ogyforthemanagementoffluidcongestionrequiresmedicalaction
inpatientsthathaveanearlyevent,butonlyinpatientsthatare tobetaken,potentiallyintheabsenceofsymptoms.WithinOpti-
event-freeat6months. LinkHF,the proportionof eventswithpriorFTCishighestfor
HF-related hospitalizations, as expected. However, onlyone in
Discussion three HF hospitalizations had a prior crossing. Consequently,
assumingcrossings .30daysbeforehospitalizationareunrelated
IntheOptiLinkHFstudy,useofaspecificintrathoracicimpedance totheevent,atbest,oneinthreeHFhospitalizationscouldhave
andtelemedicine-basedHFdiseasemanagementstrategyinpatients beenpreventedbytheOptiLinkHFintervention.
withmoderate-to-severeHF,severeleftventriculardysfunction, WhiletheOptiLinkHFstudyusedaprescriptiveintervention
andpriorimplantationofanICD/CRT-Ddevicedidnotsignificantly algorithm,medicationchanges, andmedicalactionswereatthe
reducetherateofall-causedeathorCVhospitalizationcompared discretionoftheinvestigator.Weobservedthat30%ofFTCsled
withstandardclinicalassessment.Inaddition,thesecondarymorbidity tomedicalactionand26%tomedicationchange.Morespecifically,
andmortalityoutcomesdidnotshowastatisticallysignificantbenefit. onaverage,patientsintheinterventionarmhad0.37HFmedication
TheeffectsoftelemonitoringwithinOptiLinkHFdependedupon changesper6monthsasaresultofTAEFalgorithms.Conversely,
multiplefactorsincludingtheperformanceofthedevice,successful Adamsonetal.17reportedanaverageincrementalrateof5.8device-
transmissionofFTCs,physicianfollow-up,subsequentintervention/ drivenmedicationchangesper6monthsforreducedEFpatients
medicalaction,andpatientadherence.Theintrathoracicimpedance with daily ambulatory pulmonary artery pressure monitoring
monitoringfeaturehasbeenpreviouslyevaluated,demonstrating (9.5changesinthetreatmentvs.3.7inthecontrolsubjects).
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Page8of10 M.Bo¨hmetal.
Figure4 Flowdiagramdepictinginterventionsfollowingafluidthresholdcrossinginthetreatmentarm.
Fromtheanalysesperformeditmustbeconcludedthattherate 18monthscomparedwithpatientscontinuedinthestudy.Another
oftelemonitor-guidedmedicalinterventionwaslow.Intervention limitationisthepotentialheterogenoustreatmentoftheinterven-
followinganFTCwas30%,andtherewasnorecordofanyinterven- tion patients, with some physicians being more aggressive than
tionin38ofthe110CVhospitalizationswhichoccurredwithin others in responding to alerts. However, this phenomenon is
30daysofanFTC.Sincepatientsandinvestigatorswerecarefully inflictedineverytrialwherephysiciansmustreactaccordingtotheir
introducedtotheuseofthedeviceandtheapplicationofthepre- usual medical practice. Also, as the study was only conducted
definedtreatmentalgorithmatentryandduringfollow-upofthe inGermanytheresultsmaynotapplytoseveralotherregions.In
study, the reported intervention rate may more closely reflect addition,therewasaninabilitytomaskpatientsandinvestigators
reallifepractice,highlightingchallengesassociatedwithreliable to the treatment allocation inherent with the technology used
datatransmissionandconfidenceinfluidindexalgorithms. creatingapotentialbias.
The success of telemonitoring isdependentonboth optimal Inconclusion,OptiLinkHFdidnotshowabenefitofearlydetection
physicianreaction toalerts and optimal monitoring ofpatients. ofcongestionusingaremotefluidindexalertsystemonthecomposite
Centralizedmonitoringwithanassociatedcallcentrecouldhave ofall-causedeathandcardiovascularhospitalizations.Physicianand
ledto animprovementof these conditions.However,OptiLink patientadherencetotelemonitoringsystems,whicharepracticaland
HF was designed to create conditions, which are practical and affordable,representsamajorandunderappreciatedchallenge.
affordableinreallife.Therefore,itwasdecidednottouseacentral
Supplementary material
monitoring unit but to relyon appropriate clinical response to
telemonitoring.Thelowrateoftelemonitor-guidedmedicalinter-
SupplementarymaterialisavailableatEuropeanHeartJournalonline.
ventionmayreflecttheneedtoinvestadditionaleffortintoeduca-
tionalactivitiestotrainphysicianstoreacttotelemonitoringdata, Authors’ contributions
eventuallyalsoinpatientsbeforesymtomsdevelop.Inaddition,
effortstoimprovethetechnologyofdatatransmissionfortelemo- B.G.andJ.M.performedstatisticalanalysis;M.B.andJ.B.handled
nitoring arewarranted. Resultsfromour trial highlighted these fundingandsupervision;D.B.,M.B.,R.B.,J.B.,C.B.,B.G.,B.H.,C.I.,
challengesintelemonitor-guidedHFdiseasemanagement. S.K., G.K.,J.M., H.O.,and K.R. acquired the data; J.B., M.B.,R.B.,
Alimitationofthestudywastheoptionalextendedfollow-up C.B.,H.D.,B.G.,G.K.,andK.R.conceivedanddesignedtheresearch;
beyond18months.However,nodifferencesinbaselinecharacter- M.B.andB.G.draftedthemanuscript;Allmadecriticalrevisionof
isticswereobservedbetweenpatientswithfollow-upcompletedat themanuscriptforkeyintellectualcontent.
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Fluidstatustelemedicinealertsforheartfailure Page9of10
Acknowledgements D.Puplat(AsklepiosKlinikSchwalmstadt);M.Ringwald(Kardiolo-
gischePraxisBruchsal);D.Ba¨nsch(Universita¨tsklinikumRostock);
TheauthorsthankHarrisonHudnallandDedraFagan(Medtronic,
M. Bo¨hm (Universita¨tsklinikum Homburg-Saar); K. Gutleben
PLC)fortheirassistanceinthepreparationofthismanuscript.
(Herz-undDiabetesZentrumBadOeynhausen);K.Seidl(Klinikum
Funding Ingolstadt);U.Tebbe(KlinikumLippe-Detmold);K.Mischke(Uni-
TheOptiLinkHFStudywassponsoredandfundedbyMedtronicPLC, versita¨tsklinikumAachen);Chr.Perings(St.MarienHospitalLu¨nen);
(Minneapolis,MN,USA).Thefunderassistedindataanalysesandprepar- M.Haude(LukaskrankenhausNeuss);A.Knapp(Kardiologische
ingthisreport.Theauthorsareresponsibleforthedesignandconductof Praxis Parchim); B. Zrenner (Krankenhaus Landshut-Achdorf);
thisstudy,datainterpretation,andthedraftingandeditingofthepaper V.Scha¨chinger(KlinikumFulda);J.Schmitt (Universita¨tsklinikum
anditsfinalcontents.Statisticalsupportforthepaperandforthestudy Giessen);S.Willems(Universita¨tsklinikumHamburg-Eppendorf);
designwasprovidedbythefunder(B.G.,J.M.).Thecorrespondingauthor
Chr. Stellbrink (Sta¨dtisches Klinikum Bielefeld); M. Hinterseer
hadfullaccesstoallstudydataandhadfinalresponsibilityforthedecision
(KlinikFu¨ssen);R.Erbel(Universita¨tsklinikumEssen);E.Hoffmann
tosubmitthepublication.
(Sta¨dtischesKlinikumMu¨nchen-Bogenhausen);C.Felder(Kardiolo-
gischePraxisKo¨ln);U.Sechtem(Robert-BoschKrankenhausStutt-
Conflictofinterest:M.B.,H.O.,K.R.,R.B.,C.B.,G.K.,C.I.,D.B.,S.K.,
gart); H. Killat (Kardiologische Praxis Hassloch); M. Sotiriou
B.H.,J.B.haveallreceivedgrantsupportfromthestudysponsor.B.G.
(KardiologischePraxisWiesbaden);J.Schwab(Universita¨tsklinikum
andJ.M.areemployeesofMedtronic.
Bonn);S.Kuster(DRK-KrankenhausRatzeburg);F.Nagel(Kardiolo-
gische Praxis Augsburg); U. Fossmeyer (Kardiologische Praxis
Appendix
Traben-Trabach);S.Ruppert (KardiologischePraxisNu¨rtingen);
W.Raut(KrankenhausBuchholz);D.Ja¨ger(KlinikumFriedrichsha-
Study committees
fen);G.Mentz(KardiologischePraxisMainz);J.Schlichting(Kardio-
logischePraxisHerne);H.Keller(KardiologischePraxisCoburg); Executive committee
T.Markert(KardiologischePraxisGaggenau);R.Jochheim(Kardio-
TheExecutiveBoardconsistingofsixphysiciansfacilitating. logische Praxis Hattingen); K. Jocham (Kardiologische Praxis
Members:M.Bo¨hm,J.Brachmann,K.Rybak,G.Klein,R.Bosch, Memmingen);Th.Muenzel(Universita¨tsklinikumMainz);K.Goehl
andC.Butter. (Klinikum Nu¨rnberg-Su¨d); H.P. Schultheiss (Charite Berlin);
B.Lemke(Ma¨rkischeKlinikenLu¨denscheid);P.Mahr(Kardiologische
Event adjudication committee
PraxisWiesbaden);Chr.Weiss(Sta¨dtischesKlinikumLu¨neburg);
TheEventAdjudicationCommitteeconsistingofthreeindependent Th. Wetzel (Kardiologische Praxis Dortmund); J. Stachowitz
physicianstoadjudicateeventsforstudyobjectivesanddocument (St.VincenzKrankenhausPaderborn);M.Gawaz(Universita¨tsklini-
eventclassifications. kum Tu¨bingen); R. Gradaus (Klinikum Kassel); H. Fahlenbrach
Members:M.Haass,W.Haverkamp,andS.Stoerk. (Kardiologische Praxis Krefeld); S. Sack (Sta¨dtisches Klinikum
Theeventcommitteemembersdidnototherwiseparticipatein Mu¨nchen-Schwabing);B.Hammer(KreiskrankenhausSt.Ingbert);
thestudy.MedtronicpersonneldidfacilitatetheEACsessions(e.g. J.Rieber(KardiologischePraxisLeinfelden);G.Metzger(Kardiolo-
statistician,clinicaltrialleader),buttheywerenotvotingmembers. gischePraxisBochum);Th.Lawo(KlinikenBergmannsheilBochum);
TheEACwasnotmadeawareoftherandomizationassignmentof S.Brune(KardiologischePraxisStade);A.Hummel(Universita¨tskli-
studysubjects. nikumGreifswald);R.Cierpka(KardiologischePraxisHannover);
W. Hartung (Kardiologische Praxis Hannover); U. Gremmler
Data safety monitoring board
(Kardiologische Praxis Peine); G. Bauer (Kardiologische Praxis
AnindependentDataSafetyMonitoringBoardhasreviewedthe Bad Mergentheim); S. Zieger (Kardiologische Praxis Esslingen);
interim data analyses as well as periodically reviewed the total W.Haerer(KardiologischePraxisUlm);A.Hostert(Kardiologische
incidenceofAEsanddeathsinthisstudy.TheDSMBforthisstudy Praxis Bad Neuenahr); M. Boitz (Kardiologische Praxis Berlin);
consistedofmemberswithstudy-relatedbackgrounds. G.Gola(KardiologischePraxisBernau);M.Henrichs(Kardiologische
Members:S.Anker,K.Swedberg,H.Wellens,L.Tavazzi,and PraxisRangsdorf);E.Liomin(KardiologischePraxisFriedrichshafen);
S.Pocock. N.Schoen(KardiologischePraxisMu¨hldorf);S.Helbig(Kardiologische
MedtronicpersonnelfacilitatedtheDSMBsessions(e.g.clinical Praxis Nu¨rnberg); K. Droese (Kardiologische Praxis Dortmund);
trialleader,statistician),buttheywerenotvotingmembers. B.Lodde(KardiologischePraxisDortmund);W.Landgraf(Kardiolo-
gische Praxis Dortmund); Th. Fadgyas (Kardiologische Praxis
Participating German investigators
Dortmund);Chr.Kirsch(St.JosefKrankenhausSalzkotten).
(Centres)
H. Oswald (Medizinische Hochschule Hannover); J. Brachmann
References
(Klinikum Coburg); K. Rybak (Kardiologische Praxis Dessau);
1. ClelandJG,SwedbergK,FollathF,KomajdaM,Cohen-SolalA,AguilarJC,DietzR,
C.Israel(EvangelischesKrankenhausBielefeld);S.Ka¨ab(Klinikum
GavazziA,HobbsR,KorewickiJ,MadeiraHC,MoiseyevVS,PredaI,vanGilstWH,
Mu¨nchen-Grosshadern); Chr. Butter (Herzzentrum Bernau); WidimskyJ,FreemantleN,EastaughJ,MasonJ,StudyGrouponDiagnosisofthe
D. Bimmel (St. Marien Hospital Bonn); B. Huegl (Marienhaus WorkingGrouponHeartFailureoftheEuropeanSocietyofCardiology.TheEuro-
HeartFailuresurveyprogramme–asurveyonthequalityofcareamongpatients
Neuwied);Th.Heitzer(KlinikumDortmund);Y.Seivani(Klinikum
withheartfailureinEurope.Part1:patientcharacteristicsanddiagnosis.EurHeartJ
Bad Segeberg); R. Bosch (Cardio Centrum Ludwigsburg); 2003;24:442–463.
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
Page10of10 M.Bo¨hmetal.
2. BuiAL,HorwichTB,FonarowGC.Epidemiologyandriskprofileofheartfailure. 10. Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A,
NatRevCardiol2011;8:30–41. BrachmannJ,LewalterT,GoetteA,BlockM,KautznerJ,SackS,HusserD,
3. McMurrayJJ,AdamopoulosS,AnkerSD,AuricchioA,BohmM,DicksteinK,FalkV, PiorkowskiC,SogaardP,IN-TIMEstudygroup.Implant-basedmultiparameter
Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, telemonitoringofpatientswithheartfailure(IN-TIME):arandomisedcontrolled
MaggioniAP,ParkhomenkoA,PieskeBM,PopescuBA,RonnevikPK,RuttenFH, trial.Lancet2014;384:583–590.
SchwitterJ,SeferovicP,StepinskaJ,TrindadePT,VoorsAA,ZannadF,ZeiherA. 11. Parthiban N, Esterman A, Mahajan R, Twomey DJ, Pathak RK, Lau DH,
ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure Roberts-ThomsonKC,YoungGD,SandersP,GanesanAN.Remotemonitoring
2012:TheTaskForcefortheDiagnosisandTreatmentofAcuteandChronicHeart ofimplantablecardioverter-defibrillators:asystematicreviewandmeta-analysis
Failure2012oftheEuropeanSocietyofCardiology.Developedincollaborationwith ofclinicaloutcomes.JAmCollCardiol2015;65:2591–2600.
theHeartFailureAssociation(HFA)oftheESC.EurHeartJ2012;33:1787–1847. 12. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
4. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR,
Poole-WilsonPA,StrombergA,vanVeldhuisenDJ,AtarD,HoesAW,KerenA,
AbrahamWT,BerkowitzRL,GalvaoM,HortonDP,ADHEREScientificAdvisory
MebazaaA,NieminenM,PrioriSG,SwedbergK.ESCguidelinesforthediagnosis
CommitteeInvestigators.Characteristicsandoutcomesofpatientshospitalizedfor
andtreatmentofacuteandchronicheartfailure2008:theTaskForceforthe
heartfailureintheUnitedStates:rationale,design,andpreliminaryobservations
diagnosisandtreatmentofacuteandchronicheartfailure2008oftheEuropean
fromthefirst100,000casesintheAcuteDecompensatedHeartFailureNational
SocietyofCardiology.DevelopedincollaborationwiththeHeartFailureAssoci-
Registry(ADHERE).AmHeartJ2005;149:209–216.
ationoftheESC(HFA)andendorsedbytheEuropeanSocietyofIntensiveCare
5. AbrahamWT,AdamsonPB,BourgeRC,AaronMF,CostanzoMR,StevensonLW,
Medicine(ESICM).EurJHeartFail2008;10:933–989.
StricklandW,NeelagaruS,RavalN,KruegerS,WeinerS,ShavelleD,JeffriesB,
13. BrachmannJ,BohmM,RybakK,KleinG,ButterC,KlemmH,SchomburgR,
YadavJS,CHAMPTIONTrialStudyGroup.Wirelesspulmonaryarteryhaemo-
SiebermairJ,IsraelC,SinhaAM,DrexlerH,OptiLinkHF,StudyExecutiveBoard,
dynamicmonitoringinchronicheartfailure:arandomisedcontrolledtrial.Lancet
Investigators. Fluid status monitoring with a wireless network to reduce
2011;377:658–666.
cardiovascular-relatedhospitalizationsandmortalityinheartfailure:rationale
6. BourgeRC,AbrahamWT,AdamsonPB,AaronMF,ArandaJMJr,MagalskiA,
Zile MR, Smith AL, Smart FW, O’Shaughnessy MA, Jessup ML, Sparks B, anddesignoftheOptiLinkHFStudy(OptimizationofHeartFailureManagement
NaftelDL,StevensonLW,COMPASS-HFStudyGroup.Randomizedcontrolled usingOptiVolFluidStatusMonitoringandCareLink).EurJHeartFail2011;13:
trialofanimplantablecontinuoushemodynamicmonitorinpatientswithadvanced 796–804.
heartfailure:theCOMPASS-HFstudy.JAmCollCardiol2008;51:1073–1079. 14. TangWH,WarmanEN,JohnsonJW,SmallRS,HeywoodJT.Thresholdcrossing
7. vanVeldhuisenDJ,BraunschweigF,ConraadsV,FordI,CowieMR,JondeauG, ofdevice-basedintrathoracicimpedancetrendsidentifiesrelativelyincreased
KautznerJ,AguileraRM,LunatiM,YuCM,GerritseB,BorggrefeM,DOT-HF mortalityrisk.EurHeartJ2012;33:2189–2196.
Investigators.Intrathoracicimpedancemonitoring,audiblepatientalerts,and 15. YuCM,WangL,ChauE,ChanRH,KongSL,TangMO,ChristensenJ,StadlerRW,
outcomeinpatientswithheartfailure.Circulation2011;124:1719–1726. LauCP.Intrathoracicimpedancemonitoringinpatientswithheartfailure:correl-
8. RitzemaJ,TroughtonR,MeltonI,CrozierI,DoughtyR,KrumH,WaltonA, ationwithfluidstatusandfeasibilityofearlywarningprecedinghospitalization.
Adamson P, Kar S, Shah PK, Richards M, Eigler NL, Whiting JS, Haas GJ, Circulation2005;112:841–848.
HeywoodJT,FramptonCM,AbrahamWT,HemodynamicallyGuidedHomeSelf- 16. ConraadsVM,TavazziL,SantiniM,OlivaF,GerritseB,YuCM,CowieMR.
TherapyinSevereHeartFailurePatientsStudyGroup.Physician-directedpatient Sensitivityandpositivepredictivevalueofimplantableintrathoracicimpedance
self-managementofleftatrialpressureinadvancedchronicheartfailure.Circulation monitoringasapredictorofheartfailurehospitalizations:theSENSE-HFtrial.
2010;121:1086–1095. EurHeartJ2011;32:2266–2273.
9. AbrahamWT,ComptonS,HaasG,ForemanB,CanbyRC,FishelR,McRaeS, 17. AdamsonPB,AbrahamWT,BourgeRC,CostanzoMR,HasanA,YadavC,
ToledoGB,SarkarS,HettrickDA,FASTStudyInvestigators.Intrathoracicimped- HendersonJ,CowartP,StevensonLW.Wirelesspulmonaryarterypressure
ancevsdailyweightmonitoringforpredictingworseningheartfailureevents: monitoringguidesmanagementtoreducedecompensationinheartfailurewith
resultsoftheFluidAccumulationStatusTrial(FAST).CongestHeartFail2011;17: preservedejectionfraction.CircHeartFail2014;7:935–944.
51–55.
Downloaded
from
http://eurheartj.oxfordjournals.org/
by
guest
on
June
8,
2016
